Platelet mass has prognostic value in patients with myelodysplastic syndromes

Bowles, Kristian M ORCID: https://orcid.org/0000-0003-1334-4526, Warner, Brian A and Baglin, Trevor P (2006) Platelet mass has prognostic value in patients with myelodysplastic syndromes. British Journal of Haematology, 135 (2). pp. 198-200. ISSN 0007-1048

Full text not available from this repository. (Request a copy)

Abstract

Platelet mass (mean platelet volume x platelet count) can be derived from data obtained from the routine full blood count and separates patients with myelodysplastic syndromes (MDS) at diagnosis into three distinct prognostic groups: low platelet mass group - median survival 5 months and 5-year survival 0%; intermediate platelet mass group - median survival 30 months and 5-year survival 34%; high platelet mass group median survival - not reached at 82 months follow-up with a 5-year survival of 82%. These data provide a simple rapid prognostic index at the time of diagnosis in MDS.

Item Type:	Article
Uncontrolled Keywords:	adult,aged,aged, 80 and over,blood platelets,cell size,female,humans,male,middle aged,myelodysplastic syndromes,platelet count,prognosis,survival analysis
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies
Depositing User:	Pure Connector
Date Deposited:	16 Dec 2013 15:12
Last Modified:	24 Oct 2022 05:28
URI:	https://ueaeprints.uea.ac.uk/id/eprint/45983
DOI:	10.1111/j.1365-2141.2006.06246.x

Actions (login required)

View Item